151. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.
- Author
-
Wang B, Yu XC, Xu SF, and Xu M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Apoptosis drug effects, Bone Neoplasms pathology, Cell Cycle drug effects, Cell Line, Tumor drug effects, Drug Carriers administration & dosage, Drug Carriers chemistry, Drug Carriers pharmacology, Etoposide administration & dosage, Etoposide chemistry, Humans, Lactic Acid chemistry, Osteosarcoma pathology, Paclitaxel administration & dosage, Paclitaxel chemistry, Polyglycolic Acid chemistry, Polylactic Acid-Polyglycolic Acid Copolymer, Antineoplastic Combined Chemotherapy Protocols pharmacology, Bone Neoplasms drug therapy, Nanoparticles administration & dosage, Nanoparticles chemistry, Osteosarcoma drug therapy
- Abstract
Background: The combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of cancers. Present study examines the antitumor potential of paclitaxel (PTX) and etoposide (ETP)-loaded PLGA nanoparticles for the treatment of osteosarcoma., Results: The resulting drug-loaded PLGA NP exhibited a nanosize dimension with uniform spherical morphology. The NP exhibited a sustained release profile for both PTX and ETP throughout the study period without any sign of initial burst release. The combinational drug-loaded PLGA NP enhanced the cytotoxic effect in MG63 and Saos-2 osteosarcoma cell lines, in comparison to either native drug alone or in cocktail combinations. Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner. Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis. The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs. The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic cancer therapy., Conclusion: Taken together, our study demonstrated that PTX-ETP/PLGA NP based combination therapy holds significant potential towards the treatment of osteosarcoma.
- Published
- 2015
- Full Text
- View/download PDF